Ionis

Ionis deal delivers for GSK as HBV drug hits the mark in phase 2

https://pharmaphorum.com/news/ionis-deal-delivers-for-gsk-as-hbv-drug-hits-the-mark-in-phase-2/

Pfizer inks deal with Ionis and Akcea for potential blockbuster diabetes and NASH drug

https://pharmaphorum.com/news/pfizer-inks-deal-with-ionis-and-akcea-for-potential-blockbuster-diabetes-and-nash-drug/

Akcea/Ionis’ rare disease drug Waylivra set for EU market after rejection in US

https://pharmaphorum.com/news/akcea-ionis-rare-disease-drug-waylivra-set-for-eu-market-after-rejection-in-us/

Novartis licenses lipoprotein-lowering CVD drug

https://pharmaphorum.com/news/novartis-licenses-lipoprotein-lowering-cvd-drug/

Eyeing Novartis deal, Akcea trumpets lipoprotein drug data

https://pharmaphorum.com/news/eyeing-novartis-deal-akcea-trumpets-lipoprotein-drug-data/

Alnylam’s Onpattro is first ever FDA-approved RNAi drug

https://pharmaphorum.com/news/alnylams-onpattro-first-ever-approved-rnai-drug/

Alnylam hopes for 2018 filing for RNAi liver disease drug

https://pharmaphorum.com/news/alnylam-hopes-2018-filing-rnai-liver-disease-drug/

Alnylam beats Ionis in RNA drug battle

https://pharmaphorum.com/news/sanofialnylam-improve/

Ionis hit by safety concerns, rivals Alnylam benefit

https://pharmaphorum.com/news/ionis-inotersen-meets-efficacy-targets-fap-safety-concerns-spook-investors/

1 2

Close in 10 seconds

Pharmaphorum.com

Search